No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NUVL Nuvalent
- 67.950
- +1.270+1.90%
Close May 24 16:00 ET
- 67.950
- 0.0000.00%
Post 16:02 ET
4.39BMarket Cap-28078P/E (TTM)
68.660High66.480Low257.30KVolume67.340Open66.680Pre Close17.49MTurnover0.78%Turnover RatioLossP/E (Static)64.56MShares89.39052wk High6.50P/B2.25BFloat Cap38.78052wk Low--Dividend TTM33.13MShs Float89.390Historical High--Div YieldTTM3.27%Amplitude7.090Historical Low67.957Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Nuvalent(NUVL.US) Director Sells US$345.45K in Common Stock
$Nuvalent(NUVL.US)$ Director Conley Emily sold 5,000 shares of common stock on May 15, 2024 at an average price of $69.09 for a total value of $345.45K.Source: Announcement What is statement of change
Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing
Emily Conley, Director, on May 15, 2024, sold 5,000 shares in Nuvalent (NUVL) for $345,450. Following the Form 4 filing with the SEC, Conley has control over a total of 8 shares of the company, with 8
Express News | Wedbush Reiterates Outperform on Nuvalent, Maintains $99 Price Target
Nuvalent Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 32.85% Wedbush → $99 Reiterates Outperform → Outperform 04/17/2024 30.17% Jefferies → $97 Initi
Nuvalent Gains Breakthrough Therapy Status for Non-small Cell Lung Cancer Candidate
Express News | Nuvalent Inc: Expect to Provide an Update From Alkove-1 Trial of Nvl-655 at a Medical Meeting in Second Half of This Year
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
5
$Nuvalent(NUVL.US$ beautiful 😍
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg